CLASS II ONGOING Drug recall · Reported 7 May 2025 · FDA Enforcement Report

niCARdipine Hydrochloride Injection, USP, 25 mg recalled

American Regent is recalling niCARdipine Hydrochloride Injection, USP, 25 mg/ (2.5 mg/mL) Single Dose Vial, distributed nationwide in the US. The recall was initiated on 18 Apr 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLots, expiry: Lot 24086N0C0, 7/31/2025; Lot 24076N0C0, Lot 24090N0C0, 8/31/2025, Lot 25011N0C0, 6/30/2026;
NDC0517-0735
Quantity recalled7,249 (cartons of 10 x 10 mL vials)

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0399-2025
FDA event ID
96695
Recalling firm
American Regent, New Albany, OH
Manufacturer
American Regent, Inc.
Classification
Class II
Status
Ongoing
Recall initiated
18 Apr 2025
FDA classified
1 May 2025
Reported
7 May 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Sterility

Timeline

18 Apr 2025Recall initiated by company
1 May 2025Classified by FDA+13 days
7 May 2025Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Lack of sterility assurance: Product leakage around the vial neck, which could potentially result in a lack of sterility assurance.

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

niCARdipine Hydrochloride Injection, USP, 25 mg/10 mL (2.5 mg/mL), 10 mL Single Dose Vial, Rx Only, American Regent, Inc., Shirley, NY 11967. NDC carton: 0517-0735-10 / NDC Vial: 0517-0735-01]

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Why was it recalled?

Lack of sterility assurance: Product leakage around the vial neck, which could potentially result in a lack of sterility assurance.

Which lots are affected?

Lots, expiry: Lot 24086N0C0, 7/31/2025; Lot 24076N0C0, Lot 24090N0C0, 8/31/2025, Lot 25011N0C0, 6/30/2026;

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 96695

This product is part of a recall event; the main page for the event is niCARdipine Hydrochloride Injection, USP, 25 mg recalled.

ReportedClassRecallCompanyReasonWhere
CLASS IIniCARdipine Hydrochloride Injection, USP, 25 mg recalledNicardipine HydrochlorideAmerican RegentSterilityNationwide

More recalls from American Regent

All 21

Other Nicardipine recalls

All 13